All In Biotech

Drug Trial Radar · NCT03390608

Prognostic and Predictive Factors for Small Breast Tumors

Prognosis, Prognostic Factors and Predictive Factors in Centimeter or Subcentimeter Node-negative Breast Cancer

Last checked: Nov 20, 2026Latest source record: Jan 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

35,002

Actual

Start

Jan 1, 1977

Primary completion

Dec 31, 2014

Study completion Jul 30, 2016

Sponsor

Lead sponsor
Karolinska InstitutetAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
The Swedish Society of Medicine; The Swedish Breast Cancer Association (BRO); Swedish Breast Cancer Group
First posted
Jan 4, 2018

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, up to 100 years

Summary

As written by the sponsor on the registry.

Because of mammography screening increasingly more women are diagnosed with centimeter or subcentimeter node-negative breast cancer (i.e., T1abN0); these tumors account for approximately 19% of all newly diagnosed breast cancers in Sweden. Although the long term relapse-free survival rates among patients with such tumors is as high as ≥90%, some reports suggest that certain patient subgroups may have rates \<75%. Firmly established prognostic and predictive factors for patients with T1abN0 tumors are, however, lacking. This is a nationwide, register-based cohort study investigating prognostic and predictive factors in women with centimeter or subcentimeter breast cancer. The study hypotheses are: 1) Established prognostic and/or predictive factors in overall breast cancer are prognostic and/or predictive factors also in centimeter or subcentimeter node-negative breast cancer; 2) The established relative reduction in risk of recurrence and death of adjuvant treatment for overall breast cancer are similar in centimeter or subcentimeter node-negative breast cancer.

Conditions

  • Breast Cancer

Interventions

  • Endocrine therapyDrug

    Endocrine treatment versus no endocrine therapy (in women with hormone receptor positive1 disease).

  • RadiotherapyRadiation

    Radiotherapy versus no radiotherapy.

  • HerceptinDrug

    Trastuzumab versus no trastuzumab (in women with HER2-positive disease).

  • ChemotherapyDrug

    Chemotherapy versus no chemotherapy.

  • Type of breast cancer surgeryProcedure

    Type of surgery (partial mastectomy, mastectomy, other).

  • Age at diagnosisOther

    Age at diagnosis (\<35, 35-\<50, 50-\<70, ≥70).

  • Screen detected tumorOther

    Screening detected tumor (yes, no).

  • Menopausal status at diagnosisOther

    Menopausal status (premenopausal, postmenopausal).

  • Tumor sizeOther

    Tumor size (≤5 mm, 6-≤10 mm).

  • Estrogen receptor (ER) statusOther

    ER-status (positive, negative).

  • Tumor gradeOther

    Tumor grade (1, 2, 3).

  • HER2-statusOther

    HER2-status (positive, negative).

  • Intrinsic subgroups of breast cancerOther

    Intrinsic subgroup proxy (Luminal A, Luminal B (HER2-negative), Luminal B (HER2-positive), HER2-positive (non-luminal), Triple negative).

  • Nodal statusOther

    N-status (N0, N1).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Breast cancer specific deathTime frame: January 1, 1977 to December 31, 2014

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Karolinska Instiutet

    Solna, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.